NRG Oncology NSABP B-55/BIG 6-13

A Randomized, Double‐Blind, Parallel Group, Placebo‐ Controlled Multi‐Centre Phase Iii Study To Assess The Efficacy And Safety Of Olaparib Versus Placebo as Adjuvant Treatment In Patients With Germline BRCA 1/2 Mutations And High Risk Her2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment And Neoadjuvant Or Adjuvant Chemotherapy

Read more about this trial →

← Back to available clinical trials